demonstrated significant associations between the HBV genotypes and the severity of liver disease, clinical outcomes and the response to antiviral therapies (Kramvis & Kew, 2005). Moreover, it was also demonstrated that the clinical and virological characteristics may also differ among patients infected with the same genotype (Miyakawa & Mizokami, 2003). The existence of different subtypes (subgenotypes) within same genotype helps to explain this for HBV/B, where one of the subtypes (subgenotypes) (widespread in Asia; Ba) possesses a recombination with genotype HBV/C, while another (indigenous to Japan; Bj) does not (Sugauchi *et al.*, 2003). Similarly, two subtypes (subgenotypes) have been reported for HBV/A: one of them, Aa (A′/A1) prevails in sub-Saharan Africa and South Asia, while the other, Ae (A2), is widely distributed in Europe and the USA (Bowyer *et al.*, 1997; Kramvis *et al.*, 2002; Sugauchi *et al.*, 2004). The subtypes (subgenotypes) of HBV/A show no evidence of distinguishing recombination; nevertheless, they are associated with differences in replicative activity, and in the mechanisms of HBeAg seroconversion as a result of specific nucleotide substitutions in the core promoter and precore regions (Kimbi *et al.*, 2004; Sugauchi *et al.*, 2004; Tanaka *et al.*, 2004).

The characterization of isolates from indigenous populations, especially in Africa where HBV is hyperendemic, may assist in revealing the origin of HBV and clarify the many questions about its evolutionary history (Kramvis *et al.*, 2005). The genetic diversity and distribution of HBV genotypes in Central West Africa, particularly in Cameroon, are poorly documented. No data were available for the HBV strains from Pygmies in this region. The objectives of the present study were to assess the prevalence of HBV and hepatitis C virus (HCV) markers among Bantus and Pygmies, to compare the distribution of HBV genotypes and to analyse the genomic characteristics of the HBV/A strain in Cameroon. Six full genome sequences, including four representing a new subtype (subgenotype) of HBV/A and two HBV/E strains from the Cameroonian Pygmies, were analysed.

METHODS

Blood serum samples. Blood serum samples were collected in 1994 from 544 voluntary donors, including representatives of two relatively isolated populations (Bantu and Pygmies) in Cameroon, Central West Africa. The Pygmies enrolled were from two forest encampments in the East province, and the Bantu were enrolled from five provinces across the country (Central, South, North, West and East). None of the donors had clinical symptoms of liver disease. Written informed consent was obtained from all subjects enrolled. After isolation of the serum fraction from whole blood, the samples were stored at −40 °C until use. The number of subjects studied in each group, their ages and sexes are summarized in Table 1.

Serological assays for hepatitis virus markers and HBV genotyping. HCV (anti-HCV) and HBV serological markers (HBsAg, HBeAg, anti-HBs and anti-HBc) were examined using a chemiluminescent immunoassay (Ortho Clinical Diagnostics).

HBsAg-positive samples were subjected to HBV genotyping using an enzyme-linked immunoassay (EIA) with monoclonal antibodies to type-specific epitopes of the preS2 region (Usuda *et al.*, 1999), using commercial kits (HBV Genotype EIA; Institute of Immunology Co.).

Table 1. The distribution of HBV and HCV serological markers and HBV genotypes among two populations in Cameroon

Population	Bantu (n=370)	Pygmies (n=174)	P
Male/Female*	177/188	87/82	NS†
Age (years); mean±SD	34·2±14·5	29·9±9·2	<0·05
Anti-HCV	75 (20·3 %)	4 (2·3 %)	<0·0001
HBsAg	33 (8·9 %)	13 (7·5 %)	NS
HBeAg	5 (15·2 %)	0	NS
Anti-HBs	77 (20·8 %)	17 (9·8 %)	0·001
Anti-HBc	322 (87·0 %)	150 (86·2 %)	NS
HBV/A	15 (45·5 %)	5 (38·5 %)	NS
HBV/E	13 (39·4 %)	7 (53·8 %)	NS
HBV/D	5 (15·1 %)	1 (7·7 %)	NS

*Gender and age data were not available for some of the specimens.
†NS, Not significant.

Amplification, quantification of HBV DNA and nucleotide sequencing. DNA was extracted from 27 serum samples, in which HBV/A and HBV/E had been identified by genotyping EIA: 20 (15 from Bantu and five from Pygmies) and seven (only from Pygmies), respectively. Total DNA was extracted from 100 μl serum using a QIAamp DNA mini kit (Qiagen) and suspended in 100 μl storage buffer (supplied by the kit manufacturer). A real-time PCR assay, allowing detection of up to 100 viral DNA copies ml^{-1} (Abe *et al.*, 1999), with slight modifications (Tanaka *et al.*, 2004), was used for HBV DNA screening.

Two overlapping HBV DNA fragments covering the entire genome sequence were amplified using specific primers and PCR conditions that have been described previously (Sugauchi *et al.*, 2001). Amplified HBV DNA fragments were sequenced directly using a Prism Big Dye v3.0 kit (Applied Biosystems) on an ABI 3100 DNA automated sequencer (Applied Biosystems). All sequences were analysed in both the forward and reverse directions. Complete and partial HBV genomes were assembled using GENETYX v11.0 (Software Development). The nucleotide sequence data reported in this paper appear in the GenBank/EMBL/DDBJ nucleotide sequence databases with the accession numbers AB194947–AB194955.

Sequence analysis. Sequences were aligned using the CLUSTAL W software program (Thompson *et al.*, 1997). Phylogenetic trees were constructed using neighbour-joining (NJ) analysis incorporating the six-parameter distance correction method (Gojobori *et al.*, 1982) with bootstrap test confirmation performed on 1000 resamplings using the Online Hepatitis virus database (http://s2as02.genes.nig.ac.jp/). Preliminary trees were constructed for Cameroonian HBV strains obtained in this study and corresponding data of 632 HBV genome sequences available from the GenBank/DDBJ databases (the trees are available from the authors). The final trees presented herein were constructed for Cameroonian strains together with the selected GenBank/DDBJ references including the HBV/A strains of various geographical origins, and representatives of other known human HBV genotypes.

Nucleotide divergence over complete genomes was calculated using the CLUSTAL method implemented in the MEGALIGN software (Clewley & Arnold, 1997).

Detection of recombination. All Cameroonian strains' complete genome sequences were examined for the presence of recombination with other HBV genotypes, as described previously (Robertson *et al.*, 1995). Bootscan analysis implemented in the SimPlot software program (Lole *et al.*, 1999) was performed for each of the strains.

Statistical analysis. All statistical values were calculated using the Mann–Whitney U test, Fisher's exact test and the χ^2 test with Yate's correction, implemented in the STATA v8.0 software program (Stata). Differences were considered significant for P values less than 0·05.

RESULTS

Hepatitis virus serological markers and HBV genotypes in Cameroon

Table 1 summarizes results of the serological screening and HBV genotyping. The overall anti-HCV seroprevalence was very high (14·5 %), and was significantly higher in Bantus (20·3 %) than in Pygmies (2·3 %, $P<0·0001$), demonstrating that transmission networks of the infection are relatively isolated between two populations (blood transfusion and medical procedures probably contributed to transmission in the Bantus but not in the Pygmies; Kowo *et al.*, 1995). Nevertheless, HBsAg prevalence was equally high in both



Fig. 1. A phylogenetic NJ tree constructed using the HBV preS2/S nucleotide sequences. Nine strains from Cameroon isolated in this study are indicated in bold. Reference sequences were retrieved from GenBank/EMBL/DDBJ with their accession numbers and origin (in parentheses) indicated. Bootstrap values are indicated in the tree roots. Asterisk (*) marked strains, four HBV/A and two HBV/E, from Cameroon were used for further analyses based on the complete genome sequences.

populations (8·9–7·5 %). HBeAg examined among HBsAg-positive carriers was determined in 10·9 % of cases, all of which were in the Bantus infected with HBV/E (mean age 21·2 years, range 1–30 years). The mean age of HBeAg-negative carriers in the Bantus was 31·6 years, range 17–90 years. All HBsAg-positive carriers among the Pygmies were negative for HBeAg (mean age 29·5 years, range 27–38 years). Thus, the mean age of the HBeAg-negative group was relatively young for HBsAg carriers in both populations in Cameroon, suggesting early HBeAg seroconversion. Anti-HBc seroprevalence was very high in both populations (mean 86·7 %), with no significant difference (86·2 vs 87 %), concordant with a previous report (Ndumbe *et al.*, 1993) and indicating a high incidence of HBV infection in both populations, probably attributable to effective horizontal transmission at a young age, as reported previously in African countries (Kramvis *et al.*, 2005). There was no significant difference in the distribution of the examined viral markers among the Bantu population in different provinces, or among the Pygmies population in the different encampments. A total of 46 serum samples found to be positive for HBsAg were subjected to HBV genotyping using the EIA method. Genotypes A and E identified in 43·5 % of cases were equally predominant in both of the populations, and genotype D was found in a minority (13 %) of cases. No significant difference in distribution of the genotypes was found within the same population in different provinces or between the two populations.

In order to study the molecular genetic characteristics of the prevalent HBV genotypes in Cameroon, 20 HBV/A and seven HBV/E samples, for which sufficient volume was available, were subjected to further investigation. Of the



Fig. 2. A phylogenetic NJ tree constructed using the complete HBV genome. Six strains from Cameroon isolated in this study are indicated in bold. Accession numbers are given for reference sequences retrieved from GenBank/EMBL/DDBJ. The origins of the previously published HBV/A strains are indicated in parentheses. Bootstrap values are indicated in the tree roots. The strain from Cameroon with the recombination between HBV/A and HBV/E is marked with an asterisk (*).

samples, only 1/27 was HBeAg-positive (HBV/E by EIA), which was obtained from a 1-year-old child, and the rest (26/27) of the HBsAg-positive carriers had undergone HBeAg seroconversion.

HBV DNA quantification, sequencing, phylogenetic relation and genetic diversity of HBV/A subtypes (subgenotypes)

HBV DNA was detected in only 10/27 serum samples: 5/15 Bantus and 5/12 Pygmies. The highest HBV DNA level ($3{\cdot}4\times10^{10}$ copies ml^{-1}) was detected in the sample obtained from a 1-year-old child. The rest of the nine positive samples were obtained from (mean) 26-year-old carriers (range 21–30 years), with HBV DNA levels ranging from $1{\cdot}1\times10^{3}$ to $7{\cdot}8\times10^{5}$ copies ml^{-1}. HBV DNA-negative carriers were (mean) 30·4 years old, range 17–50 years, showing a general tendency of HBV DNA level to decline with age (not statistically significant, probably due to small numbers). HBV large S coding region sequences were successfully amplified from 9/10 samples. The sequences were subjected to a similarity search throughout GenBank/DDBJ using the BLAST search engine, and the most similar strains were used for phylogenetic analysis together with the reference sequences of all known human HBV genotypes. The phylogenetic relationship of the ~800 nt (positions 31–835) preS2/S sequences of the HBV strains is represented in Fig. 1. Within the HBV/A phylogenetic cluster, the HBV/Aa (A1) and HBV/Ae (A2) strains separated out into two clusters and the five Cameroonian strains sequenced in this study together with other Cameroonian strains retrieved from GenBank/DDBJ clustered separately. The Cameroonian strains retrieved from GenBank/DDBJ were previously designated A″ cluster according to partial (Large S) genome sequence (Mulders *et al.*, 2004). The Cameroonian and HBV/Aa (A1) subclusters, however, did not have significant bootstrap indexes.



The complete genome of six strains (four HBV/A and two HBV/E) were sequenced successfully (marked by asterisks in Fig. 1). The lengths of the complete genomes corresponding to HBV/A and HBV/E were 3221 and 3212 nt, respectively. The phylogenetic analysis of the complete genome sequences (Fig. 2) revealed three distinct bootstrap test supported groups within the HBV/A cluster: HBV/Aa (A1), HBV/Ae (A2), and the third group formed by samples from Cameroon. We denoted the third phylogenetic group as 'HBV/Ac', where 'c' stands for Cameroon and Central Africa. The distinctive grouping of HBV/Ac (A3) strains was also confirmed when preS1/S2, preC/C, and complete Pol genes were analysed phylogenetically. S and X genes were phylogenetically related between the HBV/Aa (A1) and HBV/Ac (A3) groups. Estimated inter-group percentage nucleotide divergence over complete genome sequences consisted of [mean $\pm$SD (range)]: 4·9$\pm$0·4 (4·2–6·1), Aa (A1) versus Ae (A2); 5·1$\pm$0·5 (4·0–6·0), Aa (A1) versus Ac (A3); and 5·2$\pm$0·3 (4·7–5·8), Ae (A2) versus Ac (A3). On the other hand, intra-group percentage nucleotide divergence was similar for HBV/Aa (A1) and HBV/Ac (A3) [mean $\pm$SD (range)]: 3·6$\pm$0·8 (4·0–4·6) and 3·9$\pm$1·1 (1·8–4·8), respectively, and lowest for Ae (A2): 0·9$\pm$0·3 (0·4–1·6) ($P<0·0001$).



Fig. 3. (a) SimPlot analysis demonstrating the recombination in the non-overlapping part of the polymerase coding region of the CMR151 strain. The strain was subjected to bootscan analysis over the entire genome using the SimPlot program (Lole *et al.*, 1999) with a window size of 300 bp and a step size of 30 bp, under the F84 (ML) model, with bootstrap resampling performed 1000 times. Initially, consensus sequences of each human HBV genotype were used as references; after manual confirmation of the sequence alignment, the final plot was constructed using the consensus of the HBV/A, HBV/E and HBV/D genotypes only. The sequences were obtained from two overlapping PCR fragments, indicated by two lines ('A' and 'B'). HBV genome coding regions are indicated by standard abbreviations (S2, S, Pol, X, preC, C and preS1). (b) The phylogenetic NJ tree constructed using the recombinant segment. Six strains from Cameroon in this study are indicated in bold. Accession numbers are given for reference sequences retrieved from GenBank/EMBL/DDBJ. (c) Alignment of all human HBV genotype genome nucleotide sequences in the region corresponding to the recombination in the Cameroonian strain CMR151 (shaded in grey). Nucleotide positions correspond to the HBV genome reference sequence, GenBank accession no. NC_003977. Dashed lines at 882 and 1060 represent the breakpoints.

Recombination

Evidence of recombination between HBV/A and HBV/E was observed in one of the Cameroonian strains (CMR151, marked by an asterisk in Fig. 2). The result of the bootscan analysis for the complete genome sequence of the strain is presented in Fig. 3(a). The phylogenetic tree constructed using the corresponding sequence segment confirmed the grouping of the CMR151 strain together with the HBV/E strains, with strong bootstrap support (Fig. 3b). The recombinant segment corresponded to a part of the non-overlapping HBV DNA polymerase in the reverse transcriptase (RT) domain and a part of the enhancer I–X promoter. (Fig. 3c). The breakpoints at nucleotide positions 882 and 1060 were estimated by mapping the informative sites and using χ^2 confirmation (Robertson *et al.*, 1995).

Enhancer/promoter elements and amino acid characteristics of the HBV/Ac (A3) strains

A comparison of the nucleotide substitutions within the *cis*-acting elements among the four HBV/Ac (A3) strains and the consensus sequences of the HBV/Aa (A1) and HBV/Ae (A2) subtypes (subgenotypes) as well as the other HBV genotypes (including HBV/Ba, Bj, B2, B1) are summarized in Table 2. Nine specific nucleotide substitutions were found in HBV/Ac (A3) strains: $G^{1173}A$ (enhancer I–X promoter), $C^{1473}G$, $G^{1512}A$ and $C^{1703}T$ (enhancer II–core promoter), $A^{2742}G$ (S1–promoter), $C^{3021}T$, $C^{3042}T$,

Table 2. Subtype (subgenotype) specific sites (bold) within enhancers and promoter regions of HBV/Aa (A1), HBV/Ac (A3) and HBV/Ae (A2)

Nucleotide positions correspond to the HBV genome reference sequence, GenBank accession no. NC_003977. Consensus sequences were composed according to 60 % or higher incidence at the corresponding nucleotide position.

Region	Position (nt)	HBV/Aa (A1)	HBV/Ac (A3)				HBV/Ae (A2)
			CMR711	CMR82	CMR983	CMR151	
Enhancer I–X promoter (950–1350)	963	C	T	T	T	T	T
	1041	T	A	A	A	G	A
	1173	G	–	**A**	**A**	**A**	–
	1320	A	A	A	A	A	**G**
	1350	**T**	–	–	–	–	C
Enhancer II-core promoter (1400–1850)	1404	**T**	–	–	–	–	C
	1464	**G**	T	T	T	T	T
	1473	C	**G**	**G**	–	**T**	–
	1484	A	–	–	–	–	**C**
	1511	G	–	–	–	–	**A**
	1512	**T**	**A**	**A**	–	**A**	**G**
	1703	C	**T**	**T**	**T**	A	–
	1727	A	–	–	–	–	**G**
	1740	T	–	–	–	–	**C**
	1809–1812	**TCAT**	-TC-	--C-	----	G--C	G--C
Encapsidation signal (1846–1908)	1888	**A**	G	G	G	G	G
S1–Promoter (2716–2806)	2720	**A**	T	T	T	T	**G**
	2742	A	**G**	**G**	**G**	**G**	–
	2744	C	**A**	**A**	–	–	–
	2777	G	C	T	T	T	**T**
S2–Promoter (2999–3219)	3013–3014	**CA**	--	--	--	--	**GC**
	3021	C	**T**	**T**	**T**	**T**	–
	3042	C	**T**	**T**	**T**	–	–
	3052	T	–	–	–	–	**C**
	3057/60	T/C	C/T	C/T	C/T	C/T	**C/T**
	3069	A	–	–	–	–	**C**
	3072–3073	TG	A-	C-	--	--	**-A**
	3076	T	**C**	**C**	**C**	**C**	–
	3111	**T**	**T**	**T**	**T**	**T**	**C**
	3118	C	–	–	–	–	**T**
	3121	G	–	–	–	–	**A**
	3124	G	–	–	–	–	**A**

$T^{3076}C$ and $C^{3111}T$ (S2–promoter). Interestingly, three of four strains had substitutions in the Kozak sequence (1809–1812) (Ahn *et al.*, 2003; Tanaka *et al.*, 2004), and two had a basal core promoter double mutation (1762/1764).

Although HBV/Ac (A3) amino acid motifs in general were more similar to HBV/Aa (A1) than to HBV/Ae (A2) motifs, HBV/Ac (A3) strains had some specific sites: Thr^{84} in preS1, Ala^{146} in Pol/terminal protein, Ser^{239}, Trp^{246}, Ser^{257} in Pol/spacer, Asp^{356}, Arg^{501}, Ser^{607} in Pol/RT, and Thr^{47} in X proteins when compared with consensus sequences composed according to 60 % or higher incidence at the corresponding amino acid position (Table 3). Pre-core/core amino acid patterns had no specific substitutions among HBV/A subtypes (subgenotypes).

Table 3. Subtype (subgenotype) specific sites (bold) in amino acid sequences of HBV/Aa (A1), HBV/Ac (A3) and HBV/Ae (A2)

Consensus sequences were composed according to 60 % or higher incidence at the corresponding amino acid position.

ORF	Position (aa)	HBV/Aa (A1)	HBV/Ac (A3)				HBV/Ae (A2)
			CMR711	CMR82	CMR983	CMR151	
PreS1	54	Q	–	–	–	–	A
	67	F	–	–	–	–	L
	74	V	–	–	–	–	I
	84	I	T	T	T	–	–
	86	A	T	T	T	T	T
	89	P	–	–	–	–	S
	90	A	–	–	–	–	T
	91	V	–	–	–	–	I
PreS2	32	L	V	V	V	V	V
	47	S	–	–	–	–	A
S	209	L	–	–	–	–	V
Pol/terminal protein	17	E	G	G	G	G	G
	33	E	–	–	A	A	A
	74	P	Q	Q	–	–	–
	102	T	N	N	–	–	–
	120	N	–	–	–	–	T
	146	T	A	A	A	A	–
Pol/spacer	236	T	–	–	–	–	S
	239	P	S	S	S	S	–
	246	R	W	W	W	–	–
	257	F	S	S	S	S	–
	269	Y	–	–	–	–	H
	271	A	–	–	–	–	V
	273	S	–	–	–	–	N
	308	S	K	K	–	–	C
	334	Q	–	–	K	K	K
	338	K	E	E	E	E	E
	348	L	–	–	–	–	R
Pol/RT	356	E	D	–	D	D	–
	501	W	R	R	R	R	–
	607	T	S	S	A	S	–
	617	I	L	L	–	–	–
	619	H	–	–	D	D	–
	666	K	R	R	–	–	–
X region	11	S	–	–	–	–	P
	31	A	S	S	S	S	S
	34	L	V	V	–	F	–
	47	S	T	T	–	T	A
	146	S	F	–	–	A	A
	147	S	–	–	–	P	P

DISCUSSION

A previous study carried out in Cameroon among the Bantus and the Pygmies (Kowo *et al.*, 1995) demonstrated a high (18·6 %) overall seroprevalence of HCV, which was significantly higher in Bantus (31·7 %) than in Pygmies (11·1 %). The results of the present study also indicate the very high HCV seroprevalence (14·5 %), and support the difference between the two populations. However, in our study, HCV seroprevalence among the Pygmies was lower (2·3 %), which might be attributed to the younger age of examined subjects compared with the cohort previously studied (Kowo *et al.*, 1995). The difference in HCV seroprevalence between the two populations might be explained by exposure of the Bantus to transmission routes such as medical procedures and blood transfusion, to which the Pygmies are not exposed. However, HBV seroprevalence (HBsAg and anti-HBc) was equally high among the two populations and different regions of the country, which is concordant with previous data (Ndumbe *et al.*, 1993). Further epidemiological investigation is required to evaluate factors contributing to the difference in HBV and HCV transmission in the Pygmies, in contrast with neighbouring Bantus.

The only data available on HBV genotypes in Cameroon demonstrated the predominant prevalence of HBV/A in human immunodeficiency virus-positive cohort (Mulders *et al.*, 2004). The present study revealed that both HBV/A and HBV/E are distributed equally in both native populations in Cameroon. The phylogenetic analysis revealed a close relationship in the large S coding region among the Cameroonian strains sequenced in this study and those from the same country available from previous reports (Mulders *et al.*, 2004; Norder *et al.*, 1992). Based on phylogenetic analysis of the complete genome, including four sequences in this study, the presence of a third phylogenetic cluster was confirmed within HBV/A in this study. The cluster was distinct from known HBV/Aa (A1) and HBV/Ae (A2) subtypes (subgenotypes), and designated HBV/Ac (A3) (where 'c' stands for Cameroon and Central Africa). The inter-subtype (subgenotype) nucleotide divergence over the complete genome sequences falls within the 4–8 % range that justifies the classification of HBV/Ac (A3) into a distinct subtype (subgenotype) according to the recent proposals on HBV nomenclature (Kato *et al.*, 2005; Kramvis *et al.*, 2005). The high intra-subtype (subgenotype) nucleotide divergence of four HBV/Ac (A3) complete genomes suggests a long natural history of this subtype (subgenotype) within the native population of Cameroon, as has been reported for subtype (subgenotype) HBV/Aa (A1) in southern African Blacks (Kimbi *et al.*, 2004). On the other hand, HBV/E strains obtained from the Pygmies did not group together separately from the strains isolated in different geographical regions, even though the Pygmies represent an isolated population in Africa. The presence of low divergent HBV/E genotype among the Pygmies might not support the hypotheses proposed previously that HBV/E has a very short history in humans (Mulders *et al.*, 2004).

The newly described subtype (subgenotype) HBV/Ac (A3) possesses a combination of the sites specific for either HBV/Aa (A1) or HBV/Ae (A2) within the corresponding enhancer/promoter elements and amino acid motifs (Kimbi *et al.*, 2004; Sugauchi *et al.*, 2004; Tanaka *et al.*, 2004). Moreover, the subtype (subgenotype) also has HBV/Ac (A3) unique substitutions. The recombination affecting a short, non-overlapping segment of the polymerase RT domain found in one of the Cameroonian strains is the first event documented to have occurred between HBV/A and HBV/E. The sequencing data generated in the present study could be used to design assays that can discriminate between HBV/Ac (A3) and the other subtypes (subgenotypes) of HBV/A in order to characterize its clinical–virological features. Cohort studies are required to investigate a possible association of HBV/Ac (A3) infection with early HBeAg/anti-HBe seroconversion and low HBV DNA levels in carriers indicated by the tendencies observed on the small number investigated in present study.

At the present time, investigation of HBV molecular heterogeneity, global distribution of HBV genetic forms, including recombination and mutations as well as efficient implications of the data, is one of the major directions in the field of virus research (Kramvis *et al.*, 2005). In this respect, further standardization of the HBV nomenclature and, an efficient and logical classification should be based on a consensus of the accumulated data including recent studies.

In conclusion, the complete genome of the third subtype (subgenotype) of HBV/A, identified in Cameroon, has been analysed and unique nucleotide/amino acid substitutions have been identified within this subtype (subgenotype). The high intra-group divergence suggests that this subtype (subgenotype) represents an indigenous HBV strain with a long natural history. Recombination between this subtype (subgenotype) and genotype E is described.

ACKNOWLEDGEMENTS

Authors thank Dr A. Kramvis (Molecular Hepatology Research Unit Department of Medicine University of the Witwatersrand, Johannesburg, South Africa) for critical reading of the manuscript. This study was supported by a grant-in-aid from the Ministry of Health, Labor and Welfare of Japan (H-16-kanen-3) and Sports of Japan (1559067). F.K. supported by Hepatitis Virus Research Foundation of Japan.

REFERENCES

Abe, A., Inoue, K., Tanaka, T., Kato, J., Kajiyama, N., Kawaguchi, R., Tanaka, S., Yoshiba, M. & Kohara, M. (1999). Quantitation of hepatitis B virus genomic DNA by real-time detection PCR. *J Clin Microbiol* 37, 2899–2903.

Ahn, S. H., Kramvis, A., Kawai, S., Spangenberg, H. C., Li, J., Kimbi, G., Kew, M., Wands, J. & Tong, S. (2003). Sequence variation upstream of precore translation initiation codon reduces hepatitis B virus e antigen production. *Gastroenterology* 125, 1370–1378.

Arauz-Ruiz, P., Norder, H., Robertson, B. H. & Magnius, L. O. (2002). Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. *J Gen Virol* **83**, 2059–2073.

Bowyer, S. M., van Staden, L., Kew, M. C. & Sim, J. G. (1997). A unique segment of the hepatitis B virus group A genotype identified in isolates from South Africa. *J Gen Virol* **78**, 1719–1729.

Clewley, J. P. & Arnold, C. (1997). MEGALIGN. The multiple alignment module of LASERGENE. *Methods Mol Biol* **70**, 119–129.

Gojobori, T., Ishii, K. & Nei, M. (1982). Estimation of average number of nucleotide substitutions when the rate of substitution varies with nucleotide. *J Mol Evol* **18**, 414–423.

Kane, M. (1995). Global programme for control of hepatitis B infection. *Vaccine* **13**, S47–S49.

Kato, H., Fujiwara, K., Gish, R. G. & 9 other authors (2005). Classifying genotype F of hepatitis B virus into F1 and F2 subtypes. *World J Gastroenterol* (in press).

Kimbi, G. C., Kramvis, A. & Kew, M. C. (2004). Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa. *J Gen Virol* **85**, 1211–1220.

Kowo, M. P., Goubau, P., Ndam, E. C., Njoya, O., Sasaki, S., Seghers, V. & Kesteloot, H. (1995). Prevalence of hepatitis C virus and other blood-borne viruses in Pygmies and neighboring Bantus in southern Cameroon. *Trans R Soc Trop Med Hyg* **89**, 484–486.

Kramvis, A. & Kew, M. C. (2005). Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. *J Viral Hepat* (in press).

Kramvis, A., Weitzmann, L., Owiredu, W. K. & Kew, M. C. (2002). Analysis of the complete genome of subgroup A′ hepatitis B virus isolates from South Africa. *J Gen Virol* **83**, 835–839.

Kramvis, A., Kew, M. & Francois, G. (2005). Genotypes of hepatitis B virus. *Vaccine* **23**, 2407–2421.

Lole, K. S., Bollinger, R. C., Paranjape, R. S., Gadkari, D., Kulkarni, S. S., Novak, N. G., Ingersoll, R., Sheppard, H. W. & Ray, S. C. (1999). Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. *J Virol* **73**, 152–160.

Miyakawa, Y. & Mizokami, M. (2003). Classifying hepatitis B virus genotypes. *Intervirology* **46**, 329–338.

Mulders, M. N., Venard, V., Njayou, M. & 11 other authors (2004). Low genetic diversity despite hyperendemicity of hepatitis B virus genotype E throughout West Africa. *J Infect Dis* **190**, 400–408.

Ndumbe, P. M., Atchou, G., Biwole, M., Lobe, V. & Ayuk-Takem, J. (1993). Infections among pygmies in the Eastern Province of Cameroon. *Med Microbiol Immunol* **182**, 281–284.

Norder, H., Hammas, B., Lofdahl, S., Courouce, A. M. & Magnius, L. O. (1992). Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. *J Gen Virol* **73**, 1201–1208.

Norder, H., Courouce, A. M. & Magnius, L. O. (1994). Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. *Virology* **198**, 489–503.

Okamoto, H., Tsuda, F., Sakugawa, H., Sastrosoewignjo, R. I., Imai, M., Miyakawa, Y. & Mayumi, M. (1988). Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. *J Gen Virol* **69**, 2575–2583.

Robertson, D. L., Hahn, B. H. & Sharp, P. M. (1995). Recombination in AIDS viruses. *J Mol Evol* **40**, 249–259.

Stuyver, L., De Gendt, S., Van Geyt, C., Zoulim, F., Fried, M., Schinazi, R. F. & Rossau, R. (2000). A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. *J Gen Virol* **81**, 67–74.

Sugauchi, F., Mizokami, M., Orito, E. & 7 other authors (2001). A novel variant genotype C of hepatitis B virus identified in isolates from Australian Aborigines: complete genome sequence and phylogenetic relatedness. *J Gen Virol* **82**, 883–892.

Sugauchi, F., Orito, E., Ichida, T. & 10 other authors (2003). Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. *Gastroenterology* **124**, 925–932.

Sugauchi, F., Kumada, H., Acharya, S. A. & 10 other authors (2004). Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. *J Gen Virol* **85**, 811–820.

Tanaka, Y., Hasegawa, I., Kato, T. & 11 other authors (2004). A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. *Hepatology* **40**, 747–755.

Thompson, J. D., Gibson, T. J., Plewniak, F., Jeanmougin, F. & Higgins, D. G. (1997). The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. *Nucleic Acids Res* **25**, 4876–4882.

Usuda, S., Okamoto, H., Iwanari, H., Baba, K., Tsuda, F., Miyakawa, Y. & Mayumi, M. (1999). Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. *J Virol Methods* **80**, 97–112.

AIDS RESEARCH AND HUMAN RETROVIRUSES
Volume 21, Number 9, 2005, pp. 810–814
© Mary Ann Liebert, Inc.

Sequence Note

HIV Type 1 Subtypes in Circulation in Northern Kenya

SAMOEL A. KHAMADI,[1] WASHINGTON OCHIENG,[1] RAPHAEL W. LIHANA,[1] JOYCELINE KINYUA,[1] JOSEPH MURIUKI,[1] JOSEPH MWANGI,[1] RAPHAEL LWEMBE,[1] MICHAEL KIPTOO,[1] SAIDA OSMAN,[1] NANCY LAGAT,[1] ROGER PELLE,[2] ANNE MUIGAI,[3] JANE Y. CARTER,[4] ISAO OISHI,[5] HIROSHI ICHIMURA,[5] D.L. MWANIKI,[1] FREDRICK A. OKOTH,[1] SOLOMON MPOKE,[1] and ELIJAH M. SONGOK[1]

ABSTRACT

The genetic subtypes of HIV-1 circulating in northern Kenya have not been characterized. Here we report the partial sequencing and analysis of samples collected in the years 2003 and 2004 from 72 HIV-1-positive patients in northern Kenya, which borders Ethiopia, Somalia, and Sudan. From the analysis of partial *env* sequences, it was determined that 50% were subtype A, 39% subtype C, and 11% subtype D. This shows that in the northern border region of Kenya subtypes A and C are the dominant HIV-1 subtypes in circulation. Ethiopia is dominated mainly by HIV-1 subtype C, which incidentally is the dominant subtype in the town of Moyale, which borders Ethiopia. These results show that cross-border movements play an important role in the circulation of subtypes in Northern Kenya.

KENYA IS BORDERED IN THE NORTH by countries that have had political upheavals in the past leading to a lot of movement of populations across the borders into Kenya. These countries are Ethiopia, Somalia, and Sudan. In this region, not much is known about the circulating subtypes of HIV-1.

Work done between 1998 and 1999 shows that Sudan is dominated mainly by subtypes A, C, and D, with subtype D being the dominant circulating subtype.[1] In Ethiopia, the HIV-1 epidemic is dominated exclusively by HIV-1 C viruses[2] while in Somalia the circulating subtypes have not been clearly defined.

In this study to determine the circulating subtypes of HIV-1 in northern Kenya, HIV-1-positive patients and blood donors attending STD clinics and District hospitals in Mandera, Moyale, and Turkana District between August 2003 and April 2004 were recruited. The study subjects gave written informed consent and 3 ml of blood was collected in ethylenediaminetetraacetic acid (EDTA) tubes. Peripheral blood mononuclear cells (PBMCs) were extracted and used for polymerase chain reaction (PCR) amplification. A nested strategy was used to amplify about 450 base pairs of the *env* gene (nt 7850–8310) i.e., the gp41 region.[3] The primers used in the PCR were gp40F1 (5′-TCTTAGGAGCAGCAGGAAGCACTATGGG-3′) and gp41R1 (5′-AACGACAAAGGTGAGTATCCCTGCCTAA-3′) for the first round of PCR and primers gp46F2 (5′-ACAATTATTGTCTGGTATAGTGCAACAGCA-3′) and gp47R2 (5′-TTAAACCTATCAAGCCTCCTACTATCATTA-3′ for the nested PCR. The PCR conditions included denaturation at 94°C for 2 min, followed by 35 cycles of denaturation at 94°C for 30 sec, annealing at 50°C for 30 sec, and extension at 72°C for 60 sec, with a final extension at 72°C for 5 min. The resulting products were electrophoresed on a 1% agarose gel, stained with ethidium bromide, and visualized under ultraviolet light to identify the amplified products. The PCR products were sequenced directly using the BigDye Terminator DNA sequencing kit from Applied Biosystems. Electrophoresis and data collection were accomplished with an ABI Prism 310 genetic analyzer (Applied Biosystems, Foster City, CA). The CLUSTAL W method[4] was used to align the resulting 400–450 bp nucleotide sequences to-

[1]Kenya Medical Research Institute, [2]International Livestock Research Institute Kenya, [3]Jomo Kenyatta University of Agriculture and Technology, [4]African Medical and Research Foundation Kenya, and [5]KEMRI-JICA Project, Nairobi, Kenya.

gether with relevant reference sequences from the Los Alamos reference database.[5] Phylogenetic relationships were deduced using the neighbor-joining method.[6] The phylogenetic tree was drawn using the tree view program.[7]

Phylogenetic analysis of the *env* gp41 region of samples from 72 HIV-1-positive patients revealed that 50% (32 samples) of the samples were subtype A, 39% (28 samples) were subtype C, and 11% (8 samples) were subtype D. The results also showed a significant difference in the distribution of the HIV-1 subtypes in Turkana and Moyale. In Moyale a majority of the samples were subtype C (51%); 40% of the samples were subtype A and 9% were subtype D. Moyale contributed 82% of the total subtype C found in this region. This region borders Ethiopia where the dominant HIV-1 subtype is C. In Turkana, the dominant subtype in circulation is A (64%), while the rest is subtype C (20%) and D (16%). The number of samples from Mandera successfully analyzed was too few (2) to draw any significant conclusions. These samples were HIV-1 subtype A. The phylogeny of these viruses



FIG. 1. Phylogenetic analysis of the gp41 *env* region of HIV-1 subtypes from Moyale in northern Kenya. The simian immunodeficiency virus SIV_{cpzgab} was used as the outgroup. The sequences have been indicated by codes MYDH and MYSL denoting Moyale District Hospital and Moyale Sololo, respectively. The A subtypes clustered with references from Kenya, Gambia, and Tanzania; the C subtypes clustered together with references from Ethiopia, Uganda, Djibouti, and Botswana; and the D subtypes clustered with those from Uganda and Kenya.



FIG. 2. Phylogenetic analysis of the gp41 *env* region HIV-1 subtypes from Turkana in northern Kenya. The sequences have been indicated by codes TLHC and TKMH denoting Turkana Lobiding Health Centre and Turkana Kakuma Mission Hospital, respectively. The A subtypes in this region clustered with references from Kenya; the C subtypes clustered with references from Ethiopia, Djibouti, and Uganda; and the D subtypes from the region clustered with references from Uganda and Kenya as indicated on the tree.

is displayed in Figs. 1–3. The information available about the study subjects is shown along with the subtype in Table 1. These results indicate a different picture of HIV-1 subtypes in circulation compared to other parts of Kenya where the dominant subtype in circulation is A (70%).

SEQUENCE DATA

GenBank accession numbers (listed in Table 1) for the *env* gp41 sequences are AY697976–AY698021, AY694410–AY694411, AY693585–AY693603, and AY705732–AY705737.

ACKNOWLEDGMENTS

The KEMRI-JICA program funded this project. The work was done in collaboration with the African Medical and Research Foundation. We wish to thank the staff in Northern Kenya, i.e., in Moyale, Mandera, Kakuma, and Lokichogio hospitals, who assisted in the collection and initial processing of the samples.

TABLE 1. INFORMATION ABOUT STUDY SUBJECTS

ID	*Year*	*GenBank accession no.*	*Age (years)*	*Sex*	*Subtype (env)*
MYDH012	2003	AY698019	32	F	C
MYDH013	2003	AY698011	2	F	C
MYSL032	2003	AY697991	50	F	A1
MYDH054	2003	AY698010	34	F	C
MYDH058	2003	AY698002	34	M	C
MYDH057	2003	AY698003	20	F	C
MYDH034	2003	AY698021	23	F	A1
MYDH035	2003	AY698004	25	F	D
MYDH038	2003	AY697981	28	F	A
MYDH055	2003	AY698009	32	M	C
MYDH059	2003	AY698008	34	F	C
MYDH025	2003	AY697978	21	F	A1
MYSL033	2003	AY697984	30	F	A1
MYSL031	2003	AY697986	44	M	A
MYDH023	2003	AY698018	7	M	C
MYDH022	2003	AY697988	50	F	A1
MYDH028	2003	AY698020	26	F	A1
MYDH027	2003	AY697980	32	M	C
MYSL030	2003	AY697985	40	M	C
MYDH021	2003	AY697979	38	M	D
MYDH036	2003	AY697987	32	M	A
MYDH039	2003	AY697976	20	F	C
MYDH020	2003	AY697983	30	F	A1
MYDH038	2003	AY698005	28	F	A1
MYDH026	2003	AY697982	30	M	A1
MYDH003	2003	AY697992	35	M	C
MYDH005	2003	AY697989	40	M	C
MYDH004	2003	AY697990	45	F	C
MYDH002	2003	AY697993	45	M	C
MYDH007	2003	AY697995	20	F	C
MYDH014	2003	AY697996	25	M	C
MYDH001	2003	AY697997	25	F	C
MYDH063	2004	AY698007	35	M	A1
MYDH016	2003	AY697998	46	M	A
MYDH015	2003	AY697994	41	M	A1
MYDH019	2003	AY698017	47	M	A1
MYDH018	2003	AY698016	42	M	C
MYDH006	2003	AY697999	32	M	C
MYDH009	2003	AY698001	32	M	D
MYDH041	2003	AY698014	56	M	C
MYDH011	2003	AY698015	30	F	C
MYDH040	2003	AY698013	27	F	A
MYDH042	2003	AY698012	32	F	A1
MYDH062	2004	AY698005	38	M	D
MYDH008	2003	AY698000	50	M	C
TLHC007	2003	AY693585	28	M	A1
TLHC014	2003	AY693588	33	M	C
TLHC018	2003	AY693587	39	F	A
TLHC024	2003	AY693589	24	M	A1
TLHC034	2003	AY693597	39	F	D
TLHC040	2003	AY693596	34	F	D
TLHC004	2003	AY693591	28	F	A1
TLHC037	2003	AY693595	24	F	A1
TLHC002	2003	AY693586	16	F	A1
TLHC009	2003	AY693590	21	F	D
TLHC001	2003	AY693592	30	F	A
TLHC101	2004	AY705733	24	M	A
TLHC106	2004	AY705737	35	M	A1
TLHC107	2004	AY705732	42	M	A
TLHC109	2004	AY705734	45	F	C
TLHC111	2004	AY705735	46	M	A

TABLE 1. INFORMATION ABOUT STUDY SUBJECTS (CONT'D)

ID	*Year*	*GenBank accession no.*	*Age (years)*	*Sex*	*Subtype (env)*
TLHC112	2004	AY705736	50	M	A1
TKMH017X	2004	AY693601	30	F	C
TKMH017	2003	AY693602	40	M	C
TKMH002	2003	AY693598	20	F	A
TKMH020	2003	AY693599	24	M	C
TKMH014	2003	AY693600	30	F	A1
TKMH019	2003	AY693593	35	M	A
TKMH015	2003	AY693594	40	F	D
MADH005	2003	AY694411	37	F	A1
MADH003	2003	AY694410	20	M	A



FIG. 3. Phylogenetic analysis of the gp41 *env* region HIV-1 subtypes from Mandera in northern Kenya. The sequences have been indicated by codes MADH denoting Mandera District Hospital. The two samples were all subtype A and clustered with subtypes from Rwanda and Kenya.

REFERENCES

1. Hierholzer M, Graham RR, El Khidir I, Tasker S, Darwish M, Chapman GD, Fagbami AH, Soliman A, Birx DL, McCutchan F, and Carr JK: HIV type 1 strains from East and West Africa are intermixed in Sudan. AIDS Res Human Retroviruses 2002;18(15): 1163–1166.
2. Abebe A, Kuiken CL, Goudsmit J, Valk M, Messele T, Sahlu T, Yeneneh H, Fontanet A, De Wolf F, Rinke and De Wit TF: HIV type 1 subtype C in Addis Ababa, Ethiopia. AIDS Res Human Retroviruses 1997;13(12):1071–1075.
3. Yang C, Dash BC, Simon F, Groen G, Pieniazek D, Gao F, Hahn BH, and Lal RB: Detection of diverse variants of human immunodeficiency virus-1 groups M, N, and O and simian immunodeficiency viruses from chimpanzees by using generic *pol* and *env* primer pairs. J Infect Dis 2000;181:1791–1795.
4. Thompson JD, Higgins DG, and Gibson TJ: CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22: 4673–4680.
5. Kuiken C, Foley B, Hahn B, *et al.*: *HIV Sequence Compendium 2001.* Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
6. Saitou N and Nei M: The neighbor joining method: A new method for reconstruction of phylogenetic trees. Mol Biol Evol 1987;4: 406–425.
7. Page RDM: TREEVIEW: An application to display phylogenetic trees on personal computers. Comput Appl Biosci 1996; 12:357–358.

Address reprint requests to:
Samoel Ashimosi Khamadi
P.O. Box 54628-00200
Nairobi, Kenya

E-mail: skhamadi@nairobi.mimcom.net

Journal of Medical Virology 77:221–226 (2005)

Rapid Spread of Hepatitis C Virus Among Injecting-Drug Users in the Philippines: Implications for HIV Epidemics

Dorothy M. Agdamag,[1,2] Seiji Kageyama,[2]* Evelyn T. Alesna,[3] Rontgene M. Solante,[1] Prisca S. Leaño,[1] Anna Marie L. Heredia,[3] Ilya P. Abellanosa-Tac-An,[4] Eutiquio T. Vibal,[5] Lourdes D. Jereza,[6] and Hiroshi Ichimura[2]

[1]*STD AIDS Cooperative Central Laboratory, San Lazaro Hospital, Manila, Philippines*
[2]*Department of Viral Infection and International Health, Kanazawa University, Kanazawa, Japan*
[3]*Cebu Center for Infectious Diseases, Cebu City, Philippines*
[4]*Cebu City Health Office, Cebu City, Philippines*
[5]*Cebu Center for the Ultimate Rehabilitation of Drug Dependents, Cebu City, Philippines*
[6]*University of Southern Philippines, Cebu City, Philippines*

From the trends of human immunodeficiency virus (HIV) epidemics in South and Southeast Asia, it was postulated that an HIV epidemic would start as a blood-borne infection among injecting-drug users in the Philippines. In 2002, 560 individuals were recruited in Metro Cebu, Philippines and tested for HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) infections. The seroprevalence of anti-HCV among injecting-drug users (70.1%, 61/87) was significantly higher than those among inhalation drug users (16.3%, 7/43; $P = 0.00$; OR = 12), sex workers (0%, 0/130; $P = 0.00$; OR = ∞), antenatal clinic attendees (0%, 0/100; $P = 0.00$; OR = ∞), and students/health care workers (2%, 4/200; $P = 0.00$; OR = 115). The seroprevalence of HBsAg among injecting-drug users (10.3%, 9/87) was significantly higher than those among sex workers (2.3%, 3/130; $P = 0.01$; OR = 4.9), and antenatal clinic attendees (3%, 3/100; $P = 0.04$; OR = 3.7), but was not statistically different from those among inhalation drug users (9.3%, 4/43; $P = 0.9$) and students/health care workers (4.5%, 9/200; $P = 0.06$). None of the study population was reactive to anti-HIV antibody. The HCV strains obtained from the injecting-drug users belonged to either genotype 1a or 2b and the strains in each genotype clustered closely to each other. There was no dual infection with genotype 1a and 2b. These results suggest that the HCV infection in injecting-drug users may be emanating rapidly from limited number individuals in Metro Cebu, Philippines. ***J. Med. Virol. 77:221–226, 2005.*** © 2005 Wiley-Liss, Inc.

KEY WORDS: HCV epidemic; Injecting-drug users; genotype; source; HIV/AIDS outbreak; HIV prevalence

© 2005 WILEY-LISS, INC.

INTRODUCTION

The Philippines is one of the low prevalence countries for human immunodeficiency virus (HIV). Based on the AIDS registry of the Department of Health in the Philippines, the total number of HIV cases has increased but remained at low level at a cumulative total of 2,107 as of June 2004. The main mode of HIV transmission has been reported to be heterosexual contact since 1984. Although HIV-positive cases have appeared sporadically among sexually active populations such as sex workers, no outbreak has occurred among them in this country. However, wide-range HIV strains have been introduced in the country, that is; five HIV-1 subtypes (A, B, C, D, and F), a circulating recombinant form (CRF01_AE) [Paladin et al., 1998; Santiago et al., 1998; Espantaleon et al., 2003], a recombinant strain (*gag*-A/*env*-B) [Espantaleon et al., 2003]. Even HIV-2 [Leano et al., 2003] has been identified. Among these, HIV-1 subtype B was the most predominant, followed by CRF01_AE [Paladin et al., 1998; Santiago et al., 1998; Espantaleon et al., 2003]. The low prevalence and the variety of HIV strains in the Philippines indicate that HIV has been imported mainly from abroad and the gateway of HIV into the Philippines has been quite open.

Grant sponsor: Japan Society for the Promotion of Science; Grant numbers: 16406014, DOST-10417; Grant sponsor: The Nippon Foundation Fellowship for Asian Public Intellectuals.

*Correspondence to: Seiji Kageyama, Department of Viral Infection and International Health, Graduate School of Medical Science, Kanazawa University, 13-1, Takara-Machi, Kanazawa, 920-8640, Japan. E-mail: kageyama@med.kanazawa-u.ac.jp

Accepted 21 June 2005
DOI 10.1002/jmv.20439
Published online in Wiley InterScience (www.interscience.wiley.com)

Therefore, the migration sites and the subsequent circulation pathways of HIV have become one of the most important concerns for the prevention of an AIDS outbreak in the Philippines.

The past trend of HIV/AIDS outbreak in South and Southeast Asia reported by the World Health Organization (WHO; HIV/AIDS in Asia and the Pacific Region 2003) and others [Ruxrungtham et al., 2004] have implied that the Asian AIDS epidemic may start among injecting-drug users with secondary new infections become evident among sex workers. This is reasonable when considering the fact that the probability of HIV infection is 10-fold higher for transmission through contaminated needle sharing than that through sexual contact [Royce et al., 1997]. Therefore, it could be postulated that an HIV outbreak would start as a blood-borne infection among injecting-drug users in the low HIV-prevalence countries including the Philippines, and that the HIV outbreak could be preceded by other blood-borne infections, such as hepatitis C virus (HCV) and hepatitis B virus (HBV) infections.

HIV, HCV, and HBV are the major blood-borne pathogens, which spread among injecting-drug users via shared syringes and other injection devices [Lauer and Walker, 2001]. The seroprevalence of HCV antibody (anti-HCV) has been reported globally to be 65–90% among injecting-drug users [van den Hoek et al., 1990; Chamot et al., 1992; Crofts et al., 1993; Van Ameijden et al., 1993; Lauer and Walker, 2001; Soriano et al., 2002] and 82.9–100% among HIV-infected injecting-drug users [van Asten et al., 2004]. However, the reports on the prevalence and the characteristics of HCV and HBV have been limited in the Philippines. According to the available data, the positive rate for anti-HCV was 2.2% (9/392 tested) and the same rate was also noted for HBsAg among blood donors in 1990 [Arguillas et al., 1991], and anti-HCV was reported to be 4.6% (23/502 tested) among prison inmates [Katayama et al., 1996].

In this study, an HCV-epidemic site was identified in the Philippines and the genetic links of the HCV strains infecting injecting-drug users were analyzed to determine their migration site, circulation pathways, and the speed of transmission.

MATERIALS AND METHODS

Subjects

From June to August 2002, 560 individuals were recruited in Metro Cebu of the Philippines. Study population was categorized into five groups; injecting-drug users (n = 87), inhalation drug users (n = 43), sex workers (n = 130), antenatal clinic attendees (n = 100), and students and health care workers (n = 200). Characteristics of the study population are shown in Table I. Injecting-drug users were from two areas; an urban area where there was easy access to prohibited drugs and the drug rehabilitation centers. Injecting-drug users were identified by a pre-tested interview questionnaire conducted by trained staff. All of the 560 participants agreed to be part of the study after the researchers explained the objectives and the conduct of the study, and signified their intent to join the study by signing an informed consent form.

Serological Testing

A total of 5-ml whole blood was collected from each participant. Plasma was separated and subjected to each test.

Determine HIV-1/2 (ABBOTT JAPAN, Tokyo, Japan) and Determine HBsAg (ABBOTT JAPAN) were used for the detection of anti-HIV antibody and hepatitis B surface antigen, respectively. HCV PHA (Abbott Laboratories HCV 2nd Generation) was kindly provided by Abbott, Japan, for research purpose and was used for the detection of anti-HCV in this study. All the systems were used according to the manufacturer's instructions.

RNA Extraction, Reverse Transcription, and Polymerase Chain Reaction (PCR)

HCV-RNA was extracted from 100 μl of plasma using SMITEST EX-R&D (Genome Science Laboratories, Fukushima, Japan), and reverse-transcribed according to First-Strand cDNA Synthesis protocol (Invitrogen, Carlsbad, CA) with antisense gene-specific primers, hep32 (5′-GCDGARTACCTGGTCATAGC-3′) for NS5B regions of HCV genome. A part of NS5B region of HCV gene was amplified by nested PCR with primers, hep31b (5′-TGGGSTTCTCDTATGAYACC-3′)/hep32 in the first round, and hep33b (5′-AYACCCGMTGYTTTGACTC-3′)/hep34b (5′-CCTCCGTGAAKRCTCKCAG-3′) in the second round. Nested PCR was performed with 20 μl reaction mixture containing 2.5 mM $MgCl_2$, 200 μM each dNTP, 0.5 μM primers, and one unit of Amplitaq Gold® (Applied Biosystems, Foster City, CA). First-round PCR was done with one cycle of 94°C for 10 min, and 35 cycles of 94°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec with a final extension of 72°C for 10 min. Second-round PCR was done in the same condition except for the annealing temperature at 60°C. PCR amplification was confirmed by visualization with ethidium bromide staining of the gel [White et al., 2000].

TABLE I. Characteristics of Injecting- and Inhalation-Drug Users and Others

Population	Tested (male/female)	Mean age (range)
Injecting-drug users	87 (80/7)	30 (13–46)
Inhalation-drug users	43 (42/1)	29 (11–53)
Sex workers	130 (2/128)	25 (18–46)
Antenatal clinic attendees	100 (0/100)	26 (17–42)
Students/health care workers	200 (65/135)	31 (6–61)

Genotyping

The PCR product was subjected to nucleotide sequence determination directly with the primers of hep33b and hep34b for NS5B region. Some of the PCR-products were cloned with TOPO TA cloning kit (Invitrogen, Carlsbad, CA) and sequenced as described previously [Thompson et al., 1994]. At least 11 clones per sample were analyzed to investigate the possible co-existence of different HCV genotypes.

The sample sequences were aligned with HCV sequences from the database in STD AIDS Cooperative Central Laboratory (Manila, The Philippines) and HCV sequence database (http://gluttony.lanl.gov/content/hcv-db/combined_search/ search) by ClustalW with subsequent inspection and manual modification [Thompson et al., 1994]. The frequency of nucleotide substitution in each base of the sequences was estimated by the Kimura two-parameter method. A phylogenetic tree was constructed by the neighbor-joining method, and its reliability was estimated by 1,000 bootstrap replications. The profile of the tree was visualized with the program of Njplot [Perriere and Gouy, 1996].

Statistical Analysis

Prevalence data of HCV and HBV infection was analyzed by χ^2-test and P-value less than 0.05 was considered to be significant.

RESULTS

Prevalence of HCV, HBV, and HIV Infections

Of the 87 injecting-drug users, 61 (70.1%) were positive for anti-HCV. Twenty-eight of the injecting-drug users were recruited from an area at the downtown of Metro Cebu, and all (100%, 28/28) had anti-HCV. Of the 43 inhalation drug users, only 7 (16.3%) had anti-HCV. No one was positive for anti-HCV in the 130 sex workers and the 100 antenatal clinic patients. Among the students/health care workers (n = 200), only 4 (2%) were positive for anti-HCV (Table II). Thus, the prevalence of anti-HCV was significantly higher among injecting-drug users than inhalation drug users (P = 0.00; Odds ratio (OR) = 12, 95% Confidence interval (CI): 5–31), sex workers (P = 0.00; OR = ∞), antenatal clinic patients (P = 0.00; OR = ∞), and students/health care workers (P = 0.00; OR = 115, 95% CI: 38–346), indicating that injecting-drug use is associated significantly with HCV infection.

The seroprevalence of HBsAg among injecting-drug users (10.3%, 9/87) was significantly higher than that among sex workers (2.3%, 3/130; P = 0.01; OR = 5, 95% CI: 1–19) and antenatal clinic attendees (3.0%, 3/100; P = 0.04; OR = 4, 95% CI: 1–14), but not than that among inhalation drug users (9.3%, 4/43; P = 0.9) and students/health care workers (4.5%, 9/200; P = 0.06) (Table II).

HIV antibody was not detected in any of these groups (Table II).

Seven (8%) of the 87 injecting-drug users were dually positive for HBsAg and anti-HCV. Among other population groups, there was no dual positive case.

HCV Genotypes

Of the 61 injecting-drug users positive for anti-HCV (Table II), 52 samples were available for further analysis and 38 samples were positive by PCR with NS5B primers. Twenty-three of the PCR-positive samples were selected random and were subjected to nucleotide sequencing. The PCR products were directly sequenced and analyzed phylogenetically. A phylogenetic tree (Fig. 1) based on NS5B sequences (nucleotides, 7,975–8,196 [Choo et al., 1991]) showed two HCV genotypes, 1a and 2b. Of the 23 HCV strains examined, 15 clustered significantly with genotype 1a reference sequences (with bootstrap value 97%), and most of them sub-clustered together, while two strains (02dx02 and 02du98) did not. The remaining eight clustered significantly with genotype 2b reference sequences and formed a significant sub-cluster (with bootstrap value 96%), suggesting that the source of HCV 2b circulation among the injecting-drug users in Metro Cebu is limited and 02du49 could be a founder strain (Fig. 1).

Heterogeneity of HCV Strains in an Injecting-Drug User

To investigate the possible co-existence of different HCV genotypes in injecting-drug users, the PCR products of randomly selected 9 strains (5 genotype 1a

TABLE II. Seroprevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infections among Selected Population in Metro Cebu

Population	Tested	Positive cases (%) for:		
		HBsAg	Anti-HCV	Anti-HIV
Injecting-drug users	87	9 (10%)	61 (70)	0
Downtown of Metro Cebu[a]	28	3 (11)	28 (100)	0
Drug rehabilitation centers	59	6 (10)	33 (56)	0
Inhalation drug users[b]	43	4 (9.3)	7 (16)	0
Sex workers	130	3 (2.3)	0	0
Antenatal clinic attendees	100	3 (3.0)	0	0
Students/health care workers	200	9 (4.5)	4 (2.0)	0

[a]Clients from the downtown of Metro Cebu (n = 28) were all injecting-drug users.
[b]All the inhalation-drug users were from drug rehabilitation centers.



Fig. 1. Phylogenetic trees of 23 HCV strains (highlighted in the boxes) from injecting-drug users in Metro Cebu and 31 HCV strains from other area of the Philippines, performed on 227 nt within the NS5B region by the neighbor-joining method with GBV-B (accession no. NC 001655) as an outgroup. Analyzed samples were indicated with two digits of the collecting year at the head of the ID (e.g., 02ES). If the collecting year is unknown, IDs are shown with the symbol of "?" (e.g.,?JF). Accession numbers were used for the IDs of the genotype-known reference strains with two digits indicating genotypes at the end of the number (e.g., L23471-5a). Bootstrap values are given on the branches as percentage from 1,000 replicates.

strains: 02dz02, 02ccdm6, 02ccmk2, 02du98, and 02qq01; and 4 genotype 2b strains: 02ww8, 02ccdq4, 02ccdq5, and 02du49) were cloned. At least 11 clones per sample were sequenced in the regions of NS5B and analyzed phylogenetically. Phylogenetic trees based on NS5B sequences showed that nucleotide sequences of all the clones in each individual were homogeneous, and co-existence of genotype 1a and 2b were not observed.

DISCUSSION

In the current study, it was found that an HCV infection was epidemic in Metro Cebu of the Philippines, where 70% of injecting-drug users were positive for anti-HCV. The prevalence of anti-HCV among injecting-drug users has been reported to be 65–90% globally [van den Hoek et al., 1990; Chamot et al., 1992; Crofts et al., 1993; Van Ameijden et al., 1993], and that of Metro Cebu in our study was consistent with previous reports. Despite the high prevalence of anti-HCV positive cases among the tested injecting-drug users, HIV infection was not observed.

Like most RNA viruses, HCV exhibits genetic heterogeneity [Bukh et al., 1995; Zuckerman and Zuckerman, 1995], which has been reported even within the same individual [Houghton et al., 1991; Okamoto et al., 1991; Chen et al., 1992; Martell et al., 1992; Higashi et al., 1993]. In our study, two HCV genotypes, 1a and 2b were circulating among injecting-drug users in Metro Cebu, and each injecting-drug user had homogeneous HCV population regardless of the genotypes. These results suggest that these HCV strains have been introduced recently into injecting-drug users in Metro Cebu and spread rapidly among them. However, the origins have not been specified yet and further investigation is required.

The rate of HBsAg was found to be from 2% to 10% among the different population groups in Metro Cebu. However, there was no significant difference in the seroprevalence of HBsAg between injecting-drug users and inhalation drug users ($P = 0.85$). This may be because newly acquired HBV results in acute infection, needle sharing among injecting-drug users may not contribute to the increase in the HBV chronic infection, and HBV antigen carrier state may mainly be induced by vertical infections. For the further discussion, the detection of anti-HBs antibody will be required.

The Philippines and Indonesia are both island countries and have similar distances from Thailand and Cambodia where HIV infection is most prevalent in Asia. By the year 1999, Indonesia had been considered to be one of the low and slow HIV prevalence countries like the Philippines. However, in late 2000, sharp increase in HIV prevalence among injecting-drug users (up to over 35% in Jakarta) was noted (HIV/AIDS in Asia and the Pacific Region 2001, WHO). This increasing trend of HIV prevalence was also noted among blood donors, thereafter, suggesting that the use of contaminated needle sharing (causing HCV infection) triggered an AIDS outbreak before the increase in the number of HIV-infections through sexual transmission. As seen in Indonesia, HIV spreads first among injecting-drug users, followed by sex workers in other Asian countries especially if drug users are the clients of sex workers [Ruxrungtham et al., 2004]. However, it seems that HIV has not yet spread extremely through the blood-borne pathway in the Philippines. As shown in this study, HIV infection was very rare even among HCV-positive injecting-drug users. However, convincing evidence will be required by the further analyses with increasing the number of subjects and in geographically different places in the Philippines. Although HIV is of low prevalence, the rapid spread of HCV infection indicates that the injecting-drug users can be at highest risk in causing an AIDS epidemic in this country.

In this study, it was demonstrated that the HCV infection clustered among injecting-drug users in Metro Cebu of the Philippines. HCV infection seemed to be spreading rapidly among injecting-drug users from limited sources. Further studies must be conducted to identify the migration site(s) and the subsequent circulation mode of HCV infection more precisely, which can serve as a model for probable migration sites of HIV infections at an early phase of a possible AIDS epidemic in the Philippines.

ACKNOWLEDGMENTS

The authors are grateful to Mr. M. Villanobos for the technological assistance. Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research, 16406014 and Ronpaku Program, DOST-10417), Japan and The Nippon Foundation Fellowship for Asian Public Intellectuals, Indonesia, Japan, Malaysia, Philippines, and Thailand, supported this work.

REFERENCES

Arguillas MO, Domingo EO, Tsuda F, Mayumi M, Suzuki H. 1991. Seroepidemiology of hepatitis C virus infection in the Philippines: A preliminary study and comparison with hepatitis B virus infection among blood donors, medical personnel, and patient groups in Davao, Philippines. Gastroenterol Jpn 26:170–175.

Bukh J, Miller RH, Purcell RH. 1995. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin Liver Dis 15:41–63.

Chamot E, de Saussure P, Hirschel B, Deglon JJ, Perrin LH. 1992. Incidence of hepatitis C, hepatitis B and HIV infections among drug users in a methadone-maintenance programme. AIDS 6:430–431.

Chen PJ, Lin MH, Tai KF, Liu PC, Lin CJ, Chen DS. 1992. The Taiwanese hepatitis C virus genome: Sequence determination and mapping the 5′ termini of viral genomic and antigenomic RNA. Virology 188:102–113.

Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, Coit D, Medina-Selby R, Barr PJ, et al. 1991. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 88:2451–2455.

Crofts N, Hopper JL, Bowden DS, Breschkin AM, Milner R, Locarnini SA. 1993. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust 159:237–241.

Espantaleon A, Kageyama S, Bernardo MT, Nakano T, Leano PS, Alban P, Abrenica R, Morimatsu S, Teraoka H, Agdamag DM. 2003. The influence of the expanding HIV genetic diversity on molecular diagnosis in the Philippines. Int J STD AIDS 14:125–131.

Higashi Y, Kakumu S, Yoshioka K, Wakita T, Mizokami M, Ohba K, Ito Y, Ishikawa T, Takayanagi M, Nagai Y. 1993. Dynamics of genome change in the E2/NS1 region of hepatitis C virus in vivo. Virology 197:659–668.

Houghton M, Weiner A, Han J, Kuo G, Choo QL. 1991. Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease. Hepatology 14:381–388.

Katayama Y, Barzaga NG, Alipio A, Soetjipto XX, Doi H, Ishido S, Hotta H. 1996. Genotype analysis of hepatitis C virus among blood donors and inmates in Metro Manila, The Philippines. Microbiol Immunol 40:525–529.

Lauer GM, Walker BD. 2001. Hepatitis C virus infection. N Engl J Med 345:41–52.

Leano PS, Kageyama S, Espantaleon A, Maniar J, Iwasaki M, Saple D, Yoshihara N, Kurimura T, Agdamag DM. 2003. Introduction of human immunodeficiency virus type 2 infection in the Philippines. J Clin Microbiol 41:516–518.

Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J. 1992. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution. J Virol 66:3225–3229.

Okamoto H, Okada S, Sugiyama Y, Kurai K, Iizuka H, Machida A, Miyakawa Y, Mayumi M. 1991. Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: Comparison with Reported isolates for conserved and divergent regions. J Gen Virol 72:2697–2704.

Paladin FJ, Monzon OT, Tsuchie H, Aplasca MR, Learn GH Jr., Kurimura T. 1998. Genetic subtypes of HIV-1 in the Philippines. AIDS 12:291–300.

Perriere G, Gouy M. 1996. WWW-query: An on-line retrieval system for biological sequence banks. Biochimie 78:364–369.

Royce RA, Sena A, Cates W Jr., Cohen MS. 1997. Sexual transmission of HIV. N Engl J Med 336:1072–1078.

Ruxrungtham K, Brown T, Phanuphak P. 2004. HIV/AIDS in Asia. Lancet 364:69–82.

Santiago ML, Santiago EG, Hafalla JC, Manalo MA, Orantia L, Cajimat MN, Martin C, Cuaresma C, Dominguez CE, Borromeo ME, De Groot AS, Flanigan TP, Carpenter CC, Mayer KH, Ramirez BL. 1998. Molecular epidemiology of HIV-1 infection in the Philippines, 1985 to 1997: Transmission of subtypes B and E and potential emergence of subtypes C and F. J Acquir Immune Defic Syndr Hum Retrovirol 18:260–269.

Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Cargnel A, Mauss S, Dieterich D, Moreno S, Ferrari C, Poynard T, Rockstroh J. 2002. Care of patients with chronic hepatitis C and HIV co-infection: Recommendations from the HIV-HCV International Panel. AIDS 16:813–828.

Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673–4680.

Van Ameijden EJ, Van den Hoek JA, Mientjes GH, Coutinho RA. 1993. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol 9:255–262.

van Asten L, Verhaest I, Lamzira S, Hernandez-Aguado I, Zangerle R, Boufassa F, Rezza G, Broers B, Robertson JR, Brettle RP, McMenamin J, Prins M, Cochrane A, Simmonds P, Coutinho RA, Bruisten S. 2004. Spread of hepatitis C virus among European injection drug users infected with HIV: A phylogenetic analysis. J Infect Dis 189:292–302. Epub 2004 Jan 2008.

van den Hoek JA, van Haastrecht HJ, Goudsmit J, de Wolf F, Coutinho RA. 1990. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis 162:823–826.

White PA, Zhai X, Carter I, Zhao Y, Rawlinson WD. 2000. Simplified hepatitis C virus genotyping by heteroduplex mobility analysis. J Clin Microbiol 38:477–482.

Zuckerman AJ, Zuckerman JN. 1995. Prospects for hepatitis C vaccine. J Hepatol 22:97–100.